Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study

被引：0

作者：

Moore, Kathleen N.

Sabanathan, Dhanusha

Du, Yiqun

Duan, Huaxin

Li, Xiumin

Wang, Feng

Marathe, Omkar

Yang, Hua

Makker, Vicky

Growdon, Whitfield

Coward, Jim

Zhao, Peng

Liu, Liming

Shi, Rong

Liu, Shengxue

Gu, Wei

Qiu, Yang

Zhu, Zhongyuan

Zhang, Jian

Hamilton, Erika P.

机构：

[1] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA

[2] Macquarie Univ, Canc Inst, Sydney, Australia

[3] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China

[4] Hunan Prov Peoples Hosp, Changsha, Peoples R China

[5] Linyi Canc Hosp, Shandong, Peoples R China

[6] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[7] Inst Oncol, Lakewood, CA USA

[8] Hebei Univ, Affiliated Hosp, Baoding, Hebei, Peoples R China

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Weill Cornell Med Coll, New York, NY USA

[11] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[12] ICON Canc Ctr, Brisbane, Australia

[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China

[14] Dual Biol, Philadelphia, PA USA

[15] Dual Biol, Princeton, NJ USA

[16] Dual Biol, Shanghai, Peoples R China

[17] Dual Biol, Basking Ridge, NJ USA

[18] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China

[19] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China

[20] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3023

引用

页数：1

共 50 条

[21] A first-in-human, open-label, multi-center phase 1 study of TST003, a GREM 1 inhibitor, in subjects with locally advanced or metastatic solid tumors
Rivera, Ismael Rodriguez
Shen, Lin
Kummar, Shivaani
Barve, Minal
Germa, Caroline
Qi, Chuan
Chen, Lei
Milata, Jenny
Yao, Jenny
Shen, Li
Zhu, Xuelian
CANCER RESEARCH, 2024, 84 (06)
[22] A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
Ullenhag, Gustav J.
Yachnin, Jeffrey
Carneiro, Ana
Elison, Emma
Carlsson, Malin
Russell, Charlotte Astrid
Smith, Karin Enell
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
Gordon, Michael S.
Nemunaitis, John
Barve, Minal
Wainberg, Zev A.
Hamilton, Erika P.
Ramanathan, Ramesh K.
Sledge, George W., Jr.
Yue, Huibin
Morgan-Lappe, Susan E.
Blaney, Martha
Kasichayanula, Sreeneeranj
Motwani, Monica
Wang, Lan
Naumovski, Louie
Strickler, John H.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1988 - 1995
[24] A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.
Janku, Filip
Kauh, John S.
Tucci, Christopher
Yang, Zhao
Kania, Marek K.
Alese, Olatunji B.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Rodon, Jordi
Tawbi, Hussein A.
Thomas, Anne L.
Stoller, Ronald G.
Turtschi, Christian P.
Baselga, Jose
Sarantopoulos, John
Mahalingam, Devalingam
Shou, Yaping
Moles, Melissa A.
Yang, Lin
Granvil, Camille
Hurh, Eunju
Rose, Kristine L.
Amakye, Dereck D.
Dummer, Reinhard
Mita, Alain C.
CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909
[26] A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
George, Suzanne
Heinrich, Michael C.
Somaiah, Neeta
Oppelt, Peter
McLeod, Robert
Nishioka, Satoshi
Kundu, Madan G.
Qian, Xiaozhong
Kumar, Prasanna
Laadem, Abderrahmane
Lau, Yvonne
Tran, Brittany P.
Fallon, Maura
Dosunmu, Ololade
Shi, Julia
Naito, Yoichi
CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3659 - 3667
[27] Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors
Patel, Manish R.
Falchook, Gerald S.
Wang, Judy S.
Imedio, Esteban Rodrigo
Kumar, Sanjeev
Miah, Kowser
Mugundu, Ganesh M.
Jones, Suzanne F.
Spigel, David R.
Hamilton, Erika P.
TARGETED ONCOLOGY, 2025, 20 (01) : 127 - 138
[28] A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors
Sun, Yuping
Yu, Jinming
Tolcher, Anthony W.
Albany, Costantine
Chaudhry, Arvind
Dang, Qi
Ye, Leiguang
Yang, Fang
Liu, Baogang
Sun, Longhua
Tang, Jianjun
Xu, Lei
Zhu, Xiangyang
Yang, Yongmin
Yang, Yang
Zhan, Yifan
Li, Benke
Hou, Kexin
Zheng, Yang, Sr.
Wang, Jingjing
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[29] A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
George, Suzanne
Heinrich, Michael C.
Somaiah, Neeta
Van Tine, Brian Andrew
McLeod, Robert
Laadem, Abderrahmane
Cheng, Ben
Nishioka, Satoshi
Kundu, Madan Gopal
Qian, Xiaozhong
Lau, Yvonne Y.
Tran, Brittany
Kumar, Prasanna
Dosunmu, Ololade
Shi, Julia
Naito, Yoichi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
Carneiro, Ana
Hahn, Amanda
Ellmark, Peter
Enell Smith, Karin
Schultz, Lena
Ambarkhane, Sumeet
Yachnin, Jeffrey
Ullenhag, Gustav J.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)

← 1 2 3 4 5 →